Anti-Human IFN-β

Grouped product items
Size Price Qty
Catalog Number : 500-P32B


Produced from sera of rabbits pre-immunized with highly pure recombinant Human IFN-β. Anti-Human IFN-β specific antibody was purified by affinity chromatography employing immobilized Human IFN-β matrix.

Additional Information

Application: ELISA, Western Blot, Neutralization, Immunohistochemistry
Anti-Human IFN-β (BioGems Catalog #300-02BC)
Polyclonal Rabbit
This antibody stained formalin-fixed, paraffin-embedded sections of human normal placenta.  The recommended concentration is 0.75μg/ml with an overnight incubation at 4˚C.  An HRP-labeled polymer detection system was used with a DAB chromogen.  Heat induced antigen retrieval with a pH 6.0 sodium citrate buffer is recommended.  Optimal concentrations and conditions may vary.

Tissue samples were provided by the Cooperative Human Tissue Network, which is funded by the National Cancer Institute. 
To yield one-half maximal inhibition [ND50] of the biological activity of Human IFN-β (5.00μg/ml), a concentration of 2.5 μg/ml of this antibody is required.
Sandwich ELISA:
To detect Human IFN-β by sandwich ELISA (using 100 μl/well antibody solution) a concentration of 0.5 - 2.0 μg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with BioGems' Biotinylated Anti-Human IFN-β (60-181BT) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant Human IFN-β.
Western Blot:
To detect Human IFN-β by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 µg/ml. When used in conjunction with compatible secondary reagents, the detection limit for recombinant Human IFN-β is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
© BioGems International, Inc. All rights reserved.